Suresh Bangla

Suresh Bangla

Auto-generated profile, based on publicly available information

Suresh Bangla

Centre for Community Medicine, All India Institute of Medical Sciences, New Delhi, India

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2026 in International Journal for Equity in Health
Verified
Journal Article
Open access
PDF file
SBSuresh Bangla
Suresh Bangla
AKAnuva Kapoor
Anuva Kapoor
GJGirish Jeer
Girish Jeer
Background: Digital health technologies are fundamentally reshaping healthcare delivery, access, and governance worldwide. While these innovations offer unprecedented opportunities to extend services, particularly in resource-constrained settings, early implementation experiences from large-scale platforms such as India’s Co-WIN vaccination system and the Ayushman Bharat Digital Mission (ABDM) reveal that poorly designed digitalization can entrench or even widen existing health inequities. Despite growing recognition of these challenges, there remains an urgent need for a coherent analytical framework to understand how patterns of digital exclusion, ethical challenges, and implementation barriers interact to shape digital health outcomes across diverse healthcare systems. Objectives: This narrative review aims to: (1) synthesize current evidence on patterns and mechanisms of digital health exclusion across socioeconomic, geographic, and demographic dimensions; (2) identify key ethical and governance challenges, including informed consent, data protection, algorithmic fairness, and cybersecurity, in contemporary digital health implementations; (3) analyze implementation experiences from India and comparable low- and middle-income country (LMIC) settings; and (4) propose an integrated equity framework to guide more inclusive digital health strategies that can inform policy, practice, and future research. Methods: We undertook a narrative review of peer-reviewed literature, policy documents, and grey literature published between 2015 and 2025 to examine digital health equity, ethical governance, and implementation challenges. Relevant sources were identified through iterative, purposive searches of PubMed/MEDLINE, Scopus, Web of Science, and the WHO Global Health Library, supplemented by targeted grey literature retrieval. These searches identified 312 records; following deduplication and eligibility screening, 22 peer-reviewed and policy sources were included in the synthesis. No AI-assisted screening tools were employed. Literature addressing patterns of digital exclusion, ethical or legal considerations, and real-world implementation experiences in clinical or public health settings was conceptually and thematically synthesized to identify recurrent themes, interconnections, and critical gaps in current digital health practice. Results: Analysis revealed that digital health interventions frequently mirror and amplify offline health inequities. Structural barriers related to income, gender, geography, disability, age, and digital literacy shape who owns devices, controls personal health data, and can meaningfully engage with digital health tools. Ethical challenges, including inadequate consent pathways, fragmented data protection regimes, persistent algorithmic bias, and escalating cybersecurity risks, remain pervasive across many national programs. Implementation experiences from India and similar contexts highlight fragmented governance structures, uneven state-level adoption, limited provider capacity, and significant risks associated with “digital-by-default” service delivery models that marginalize non-digital access options. Three critical implementation gaps emerged: (1) insufficient participatory design processes, (2) weak equity monitoring systems, and (3) limited accountability mechanisms for addressing exclusion or harm. Conclusions: Digital health will not inherently advance health equity; rather, equity must be intentionally designed, systematically governed, and continuously monitored throughout the implementation lifecycle. We propose an integrated Digital Health Equity Framework that explicitly links patterns of exclusion with ethical safeguards and implementation strategies. Core components include: participatory co-design with marginalized communities, privacy-by-design and safety-by-design architectures, multi-channel service delivery that preserves non-digital pathways, routine disaggregated equity monitoring, and transparent algorithmic governance with redress mechanisms. Application of this framework can help policymakers, health system leaders, and technology developers ensure that national digital health programs, in India and globally, close rather than widen equity gaps, ultimately advancing universal health coverage through inclusive digital transformation.

31 January 2026 in Cureus
Verified
Journal Article
Open access
SBSuresh Bangla
Suresh Bangla
SRSanjay Rai
Sanjay Rai
KYKapil Yadav
Kapil Yadav
BNBaridalyne Nongkynrih
Baridalyne Nongkynrih

12 October 2026 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
SBSuresh Bangla
Suresh Bangla
KPKaveri Potaraj Potarad
Kaveri Potaraj Potarad
Cervical cancer is the fourth most common cancer in women worldwide, and India accounts for about 13% of the global burden. On 28 February 2026, India laun

22 September 2026 in Research Square
Verified
Preprint
Open access
PDF file
SBSuresh Bangla
Suresh Bangla
KMKarthik K M
Karthik K M
NWNaveet Wig
Naveet Wig
NNNeeraj Nischal
Neeraj Nischal
AKArvind Kumar
Arvind Kumar
SSSatnam Singh
Satnam Singh
Background A subset of people living with HIV (PLHIV) fail to regain adequate CD4 counts despite sustained viral suppression on antiretroviral therapy (ART), a pattern termed immuno-virological discordance. Its contribution to AIDS-defining events, non-AIDS comorbidity, and mortality is not well described in Indian ART cohorts. We assessed the burden of discordance and its clinical consequences at a tertiary government ART centre in North India. Methods We conducted an ambispective cohort study of PLHIV attending the ART centre at AIIMS, New Delhi, between January 2018 and January 2024. Adults on adherent ART for more than one year with a suppressed plasma viral load were classified as discordant (CD4 count < 250 cells/mm3) or non-discordant (CD4 count ≥ 250 cells/mm3). We compared demographic, socioeconomic, and clinical characteristics between groups using the Mann-Whitney U test for continuous variables and the chi-square or Fisher exact test for categorical variables. We defined a composite AIDS-defining event as tuberculosis or a fungal, bacterial, viral, or parasitic opportunistic infection meeting WHO stage 3/4 criteria, and a composite non-AIDS event as hypertension, type 2 diabetes, coronary artery disease, chronic kidney disease, or other organ-system disease. We estimated risk ratios (RR) with 95% confidence intervals (CI) for these composites and for all-cause mortality, and fitted a multivariable logistic regression model for predictors of discordance. Results Of 682 PLHIV analysed, 103 (15.1%) were discordant. Discordant patients were older (mean 43.4 vs 33.9 years, p < 0.001), had lower baseline CD4 counts (median 104 vs 308 cells/mm3, p < 0.001) and lower haemoglobin (11.4 vs 12.4 g/dL, p < 0.001). The composite AIDS-defining event was more common in discordant patients (50.5% vs 19.7%; RR 2.56, 95% CI 1.99–3.30), as was the composite non-AIDS event (29.1% vs 13.5%; RR 2.16, 95% CI 1.50–3.12). All-cause mortality was higher in the discordant group (8.7% vs 0.5%; RR 16.9, 95% CI 4.6–61.3). Age (adjusted odds ratio [aOR] 1.07 per year, 95% CI 1.05–1.10), lower baseline CD4 count (aOR 0.99 per cell/mm3, 95% CI 0.99-1.00), and tuberculosis (aOR 2.56, 95% CI 1.44–4.54) were independently associated with discordance. Conclusions Immuno-virological discordance affected around one in seven PLHIV in this North Indian cohort and was associated with a substantially higher burden of AIDS-defining events, non-AIDS comorbidity, and mortality. Older age, low baseline CD4 count, and tuberculosis co-infection identify patients who may benefit from closer monitoring after starting ART.